These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. FTY720/Fingolimod Reduces Synucleinopathy and Improves Gut Motility in A53T Mice: CONTRIBUTIONS OF PRO-BRAIN-DERIVED NEUROTROPHIC FACTOR (PRO-BDNF) AND MATURE BDNF. Vidal-Martínez G; Vargas-Medrano J; Gil-Tommee C; Medina D; Garza NT; Yang B; Segura-Ulate I; Dominguez SJ; Perez RG J Biol Chem; 2016 Sep; 291(39):20811-21. PubMed ID: 27528608 [TBL] [Abstract][Full Text] [Related]
23. Caffeic acid reduces A53T α-synuclein by activating JNK/Bcl-2-mediated autophagy in vitro and improves behaviour and protects dopaminergic neurons in a mouse model of Parkinson's disease. Zhang Y; Wu Q; Zhang L; Wang Q; Yang Z; Liu J; Feng L Pharmacol Res; 2019 Dec; 150():104538. PubMed ID: 31707034 [TBL] [Abstract][Full Text] [Related]
24. In silico analysis of alpha-synuclein protein variants and posttranslational modifications related to Parkinson's disease. da Silva ANR; Pereira GRC; Bonet LFS; Outeiro TF; De Mesquita JF J Cell Biochem; 2024 Mar; 125(3):e30523. PubMed ID: 38239037 [TBL] [Abstract][Full Text] [Related]
25. Fibrillation of α-synuclein triggered by bacterial endotoxin and lipid vesicles is modulated by N-terminal acetylation and familial Parkinson's disease mutations. Monteiro Neto JR; Lima VA; Follmer C FEBS J; 2024 Mar; 291(6):1151-1167. PubMed ID: 38069536 [TBL] [Abstract][Full Text] [Related]
26. The effects of the novel A53E alpha-synuclein mutation on its oligomerization and aggregation. Lázaro DF; Dias MC; Carija A; Navarro S; Madaleno CS; Tenreiro S; Ventura S; Outeiro TF Acta Neuropathol Commun; 2016 Dec; 4(1):128. PubMed ID: 27938414 [TBL] [Abstract][Full Text] [Related]
27. N-terminal acetylation mutants affect alpha-synuclein stability, protein levels and neuronal toxicity. Vinueza-Gavilanes R; Íñigo-Marco I; Larrea L; Lasa M; Carte B; Santamaría E; Fernández-Irigoyen J; Bugallo R; Aragón T; Aldabe R; Arrasate M Neurobiol Dis; 2020 Apr; 137():104781. PubMed ID: 31991248 [TBL] [Abstract][Full Text] [Related]
29. Alpha synuclein processing by MMP-3 - implications for synucleinopathies. Bluhm A; Schrempel S; Moceri S; Stieler J; Feja M; Schilling S; Schulze A; von Hörsten S; Hartlage-Rübsamen M; Richter F; Roßner S Behav Brain Res; 2022 Sep; 434():114020. PubMed ID: 35870616 [TBL] [Abstract][Full Text] [Related]
30. Alpha-synuclein pathology, microgliosis, and parvalbumin neuron loss in the amygdala associated with enhanced fear in the Thy1-aSyn model of Parkinson's disease. Torres ERS; Stanojlovic M; Zelikowsky M; Bonsberger J; Hean S; Mulligan C; Baldauf L; Fleming S; Masliah E; Chesselet MF; Fanselow MS; Richter F Neurobiol Dis; 2021 Oct; 158():105478. PubMed ID: 34390837 [TBL] [Abstract][Full Text] [Related]
31. Inhibition of fibrillization and accumulation of prefibrillar oligomers in mixtures of human and mouse alpha-synuclein. Rochet JC; Conway KA; Lansbury PT Biochemistry; 2000 Sep; 39(35):10619-26. PubMed ID: 10978144 [TBL] [Abstract][Full Text] [Related]
32. Neuroprotection of Exendin-4 by Enhanced Autophagy in a Parkinsonian Rat Model of α-Synucleinopathy. Bu LL; Liu YQ; Shen Y; Fan Y; Yu WB; Jiang DL; Tang YL; Yang YJ; Wu P; Zuo CT; Koprich JB; Liu FT; Wu JJ; Wang J Neurotherapeutics; 2021 Apr; 18(2):962-978. PubMed ID: 33723752 [TBL] [Abstract][Full Text] [Related]
33. Overexpression of alpha synuclein disrupts APP and Endolysosomal axonal trafficking in a mouse model of synucleinopathy. Lin S; Leitão ADG; Fang S; Gu Y; Barber S; Gilliard-Telefoni R; Castro A; Sung K; Shen R; Florio JB; Mante ML; Ding J; Spencer B; Masliah E; Rissman RA; Wu C Neurobiol Dis; 2023 Mar; 178():106010. PubMed ID: 36702318 [TBL] [Abstract][Full Text] [Related]
34. E46K α-synuclein pathological mutation causes cell-autonomous toxicity without altering protein turnover or aggregation. Íñigo-Marco I; Valencia M; Larrea L; Bugallo R; Martínez-Goikoetxea M; Zuriguel I; Arrasate M Proc Natl Acad Sci U S A; 2017 Sep; 114(39):E8274-E8283. PubMed ID: 28900007 [TBL] [Abstract][Full Text] [Related]
35. Do Lewy bodies contain alpha-synuclein fibrils? and Does it matter? A brief history and critical analysis of recent reports. Lashuel HA Neurobiol Dis; 2020 Jul; 141():104876. PubMed ID: 32339655 [TBL] [Abstract][Full Text] [Related]
36. DJ-1 interactions with α-synuclein attenuate aggregation and cellular toxicity in models of Parkinson's disease. Zondler L; Miller-Fleming L; Repici M; Gonçalves S; Tenreiro S; Rosado-Ramos R; Betzer C; Straatman KR; Jensen PH; Giorgini F; Outeiro TF Cell Death Dis; 2014 Jul; 5(7):e1350. PubMed ID: 25058424 [TBL] [Abstract][Full Text] [Related]
38. Hsp70 chaperone blocks α-synuclein oligomer formation via a novel engagement mechanism. Tao J; Berthet A; Citron YR; Tsiolaki PL; Stanley R; Gestwicki JE; Agard DA; McConlogue L J Biol Chem; 2021; 296():100613. PubMed ID: 33798554 [TBL] [Abstract][Full Text] [Related]
39. Potential direct role of synuclein in dopamine transport and its implications for Parkinson's disease pathogenesis. Kim M; Bezprozvanny I Biochem Biophys Res Commun; 2023 Sep; 671():18-25. PubMed ID: 37290280 [TBL] [Abstract][Full Text] [Related]
40. Mechanistic insight into the relationship between N-terminal acetylation of α-synuclein and fibril formation rates by NMR and fluorescence. Kang L; Janowska MK; Moriarty GM; Baum J PLoS One; 2013; 8(9):e75018. PubMed ID: 24058647 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]